Bausch Health 10-Q Details $1.43B Salix Impairment, $643M Note Redemption and New $50M Buyback
BHC sits 75% above its 52-week low of $4.33 on elevated volume (2.6× avg).
Summary
Bausch Health's Q3 10-Q confirms the October 28 earnings beat and discloses a $1,426 million Salix goodwill impairment, $1,714 million of nine-month operating cash flow, a $643 million note redemption and a new $50 million buyback.
Key Events · Earnings and Guidance · BHC
-
Q3 Earnings Confirmed in Full 10-Q
Q3 2026 revenue was $2,941 million, up 10% from $2,681 million, and net income attributable to Bausch Health was $436 million, or $1.16 per basic share, versus $179 million ($0.48) a year earlier.
-
$1.43B Salix Goodwill Impairment
A $1,426 million non-cash goodwill impairment on the Salix reporting unit, triggered by the January 2026 failure of two rifaximin Phase 3 trials, drove a nine-month net loss of $729 million, or $(1.95) per share.
-
Cash Build Funds Debt Paydown
Nine-month operating cash flow was $1,714 million versus $905 million a year earlier, lifting cash and equivalents to $2,485 million from $1,309 million at December 31, 2025.
-
$643M Notes to Be Redeemed
Bausch Health Americas will redeem all $643 million of 8.500% Senior Notes due 2027 on November 30, 2026 using cash on hand, terminating that indenture.
Analysis · BHC · Life Sciences
The headline Q3 beat was already out on October 28, but the full 10-Q carries the balance-sheet story. A $1,426 million non-cash goodwill impairment on the Salix unit, triggered by the January 2026 rifaximin Phase 3 failures, pushed the nine-month result to a $729 million net loss, even as Q3 net income rose to $436 million. Cash generation is the offset: $1,714 million of operating cash flow in nine months lifted cash to $2,485 million, enough to fund the announced redemption of all $643 million of 8.500% notes due 2027 from cash on hand and to support a new $50 million buyback. Debt remains the constraint at $20,168 million principal, with $3,766 million maturing in 2028 and Xifaxan generic entry expected in 2028.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BHC was trading at $7.56 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $4.33 to $8.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.